Stocks Comparison
Charles River Laboratories International vs Medpace: revenue, profit, margins and growth compared
Charles River Laboratories International brought in $4B of revenue in fiscal 2025, Medpace $2.5B in fiscal 2025. Revenue changed by -0.9% at Charles River Laboratories International and +20.0% at Medpace on the year before, so Medpace grew faster. Charles River Laboratories International kept -3.6% of its revenue as net profit, Medpace 17.8%. Free cash flow was $518.5M at Charles River Laboratories International and $681.9M at Medpace.
Side by side, latest fiscal year
| CRL | MEDP | |
|---|---|---|
| Fiscal year ended | FY2025 (December 27, 2025) | FY2025 (December 31, 2025) |
| Revenue | $4B | $2.5B |
| Revenue growth | -0.9% | +20.0% |
| Net income | -$144.3M | $451.1M |
| Net margin | -3.6% | 17.8% |
| Free cash flow | $518.5M | $681.9M |
| Free cash flow margin | 12.9% | 26.9% |
| Earnings per share (diluted) | -$2.91 | $15.28 |
| Cash | $213.8M | $497M |
| Debt | $166K | n/a |
| Price to earnings | n/a | 40.5 |
| Market value | $14B | $17.3B |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #72 of 523 · Health care | #94 of 523 · Health care |
Over the years
Questions about Charles River Laboratories International and Medpace
Which is bigger by revenue, Charles River Laboratories International or Medpace?
Charles River Laboratories International is bigger by revenue: $4B in fiscal 2025, against $2.5B for Medpace in fiscal 2025.
Which keeps more of its revenue as profit, Charles River Laboratories International or Medpace?
Charles River Laboratories International had a net margin of -3.6% in fiscal 2025; Medpace had 17.8% in fiscal 2025.
Which grew revenue faster, Charles River Laboratories International or Medpace?
In their latest fiscal years revenue changed by -0.9% at Charles River Laboratories International and +20.0% at Medpace.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.